cyclovirobuxine D

07/01/2007 - "Cvb-D is effective in treatment of myocardial ischemia in rats."
11/01/2011 - "CVB-D has effect of improving cardiac function, which may be the mechanism of anti-myocardial ischemia effect of CVB-D."
08/13/2007 - "Cyclovirobuxine D is an active compound extracted from Buxus microphylla, which has been used for treating acute myocardial ischemia in China. "
07/01/2007 - "Compared to the model group, Cvb-D (1.1 mg/kg, 2.2 mg/kg dos-age) significantly reduce myocardial damage, reduce myocardial ischemia mode rats' sigma s-t of ECG, significantly reduce cardiac tissue CPK activation and MDA content, raise the cardiac tissue SOD activation in the rats with myocardial ischemia. "
11/01/2006 - "To explore the pharmacology actions of Cyclovirobuxinum D (Cvb-D) for the myocardial ischemia and study its possible mechanism. "

11/01/2023 - "Our findings suggested that CVB-D improved mitochondrial function, leading to a reduction in ALD-induced cardiomyocyte hypertrophy. "
11/01/2023 - "Thus, CVB-D could be a beneficial drug for myocardial hypertrophy."
11/01/2023 - "The myocardial hypertrophy model was reproduced by ALD both in vitro and in vivo, and the protective effect of CVB-D on myocardium and mitochondria was evaluated by TEM, H&E, qPCR, Western blot and ChIP. "
10/01/2017 - "Treatment with Cvb-D significantly deceased left ventricle hypertrophy, improved the histopathology, hemodynamic conditions, and cardiac function in rats with cardiac hypertrophy. "
11/01/2023 - "Thus, CVB-D ameliorates ALD-induced myocardial hypertrophy by recovering mitochondrial function by activating the mutual regulation of Nrf2 and SIRT3. "

09/01/2011 - "The effect of Cyclovirobuxine D, an active ingredient from Buxus microphylla, was investigated in the potential prevention of cardiac dysfunction in rats with congestive heart failure. "
09/01/2011 - "Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction."
12/01/2012 - "Considering the relationship between cardiac function and [Ca(2+)]i, and the role of calcium cycling on regulating [Ca(2+)]i, the present study was designed to evaluate the influence of CVB-D on the calcium transient of myocytes from neonatal rats and adult heart failure (HF) rats. "
02/01/1990 - "The patients with congestive heart failure which were treated by combination of digoxin with cyclovirobuxine D were described, with good result, of which prominating effect was 45.5%. "
02/01/1990 - "[Congestive heart failure treated by a combination of cyclovirobuxine D with digoxin]."

09/01/2011 - "Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction."
09/01/2011 - "Results from the present study suggest that Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction and supports the potential for Cyclovirobuxine D as a new therapy for heart failure."
09/01/2005 - "To search for compounds for the treatment of cardiovascular diseases through prodrug structural modifications of cyclovirobuxine D, a single efficient composition distilled from Box plant in China, which was used to treat angina and myocardial infarction. "

03/01/1984 - "The beneficial effects of cyclovirobuxine D (CVBD) in coronary heart disease. "
10/01/1982 - "[Clinical observation of 546 cases of coronary heart disease treated with cyclovirobuxine D]."
06/01/1983 - "[Double blind study of the therapeutic effect of cyclovirobuxine D No. 1 on the left ventricular function in coronary heart disease]."
06/01/2014 - "Cyclovirobuxinum D (CVB-D), an alkaloid isolated from the Chinese medicinal plant Buxus microphylla, has been found to be effective to treat cardiac insufficiency, arrhythmias and coronary heart disease. "